Tracking Your Progress: Success and Monitoring

Because MIDD is a disease where a clone in the bone marrow produces abnormal proteins that clog the kidney, doctors must monitor your progress on two separate tracks: the Hematologic Response (how well the clone is suppressed) and the Renal Response (how well the kidney is recovering) ^[1][2].

Track 1: The Hematologic Response

To know if your treatment is working, your hematologist will track your markers. The markers depend on your specific subtype:

• For LCDD: Clinicians often track your Serum Free Light Chains (sFLC). The most important number to watch is the dFLC—the difference between your “involved” (abnormal) light chain and your “uninvolved” (healthy) light chain ^[3]. In some studies, achieving a dFLC of less than 40 mg/L (a threshold commonly used in AL amyloidosis) is associated with better outcomes, and reaching a Very Good Partial Response (VGPR) or Complete Response (CR) is a frequent target ^[4][3].
• For HCDD or LHCDD: The dFLC may be difficult to interpret or uninformative. Clinicians may instead use immunofixation, an M-protein, or a heavy-chain marker depending on the subtype.
• Why It Matters: Achieving a deep response is a strong predictor that your kidneys will eventually improve or stabilize ^[5][6]. However, targets should be individualized, as advanced kidney disease can also distort free-light-chain ratios.

Track 2: The Organ (Renal Response)

Your nephrologist will monitor your kidneys using two different measurements. It is vital to track both, as they do not always move in sync ^[2].

1. Proteinuria (Urine Protein): This measures how “leaky” your kidney filters are. A decrease in protein—such as a drop of 30% to 50% used in some studies—can be an early sign that the kidney is stabilizing ^[7][8].
2. eGFR (Filtering Rate): This measures how much active filtering your kidneys are doing. In some patients, the proteinuria improves while the eGFR stays the same; in others, the eGFR may improve while protein remains high ^[2][9].

Keep in mind that renal response may take months after hematologic response.

Predicting Your Long-Term Risk

In research studies, certain “baseline” factors have been shown to help doctors understand the risk of progressing to Kidney Failure or requiring dialysis.

• Current Filtering Power: Patients with a baseline eGFR of less than 20 mL/min/1.73 m² are at a higher risk for needing dialysis in the future ^[10][11].
• High Protein Levels: Starting with proteinuria above 3 grams per day is also associated with a higher risk of kidney failure ^[11].
• Biopsy Scarring: If your kidney biopsy showed severe interstitial fibrosis (advanced scarring), it is more difficult for the kidney to recover its function ^[5].

Please remember these are observational associations from selected studies, not a pass/fail forecast for you. eGFR fluctuates with hydration and medications, and proteinuria can change with blood-pressure treatment.

The Surveillance Schedule

MIDD requires long-term monitoring, but there is no universal MIDD schedule. The frequency depends on the regimen, blood counts, kidney function, and your transplant status.

• During Treatment: Blood and urine tests frequently (sometimes every 1–4 weeks) to ensure the markers are falling ^[12].
• Stable/Maintenance Phase: Tests may be spaced out (e.g., every 3 months) ^[12].
• Long-Term Monitoring: The hematology and nephrology teams should agree on a plan, which might eventually move to testing every 6 months ^[12].

The Psychological Toll

Living “lab-to-lab” can be emotionally draining. You may experience “scanxiety” or distress while waiting for your dFLC or eGFR results. It is helpful to remember that small fluctuations in these numbers are normal and do not always mean the disease is returning. Focus on the individualized trend of your numbers rather than any single daily result.